Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures

NCT00060996 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Critical Limb Ischemia
Peripheral Vascular Disease
Foot Ulcers
Rest Leg Pain

Interventions

DRUG: Remodulin® (treprostinil sodium) Injection

Sponsor

United Therapeutics